Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development
Reference number: GID-TA11087
Expected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia has now been combined as one appraisal. The ID number to be used for this combined appraisal is ID6232